纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | DDH2 |
Uniprot No | P52895 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 1-323aa |
氨基酸序列 | MDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEAVKLAIEAGFHHIDSAHVYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWSNSHRPELVRPALERSLKNLQLDYVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAMEKCKDAGLAKSIGVSNFNHRLLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEY |
预测分子量 | 52.7kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是几篇与“DDH2重组蛋白”相关的参考文献示例(注:由于“DDH2”可能是特定领域术语或缩写,以下内容为假设性示例,建议核实具体研究背景或修正关键词):
---
1. **文献名称**:*Expression and Purification of Recombinant DDH2 in Escherichia coli for Functional Studies*
**作者**:Zhang L., et al.
**摘要**:本研究报道了在大肠杆菌系统中高效表达DDH2重组蛋白的优化策略,通过亲和层析纯化获得高纯度蛋白,并验证其体外催化活性,为后续结构解析提供基础。
2. **文献名称**:*DDH2-Mediated Metabolic Regulation in Tumor Microenvironment*
**作者**:Wang Y., et al.
**摘要**:探讨了重组DDH2蛋白在肿瘤细胞能量代谢中的作用,发现其通过调控NAD+/NADH平衡影响癌细胞增殖,提示其作为潜在治疗靶点。
3. **文献名称**:*Structural Insights into DDH2: A Cryo-EM Study of the Recombinant Protein Complex*
**作者**:Chen H., et al.
**摘要**:利用冷冻电镜解析了重组DDH2蛋白的三维结构,揭示了其底物结合位点及变构调控机制,为抑制剂设计提供结构基础。
---
**注意事项**:
- 若实际检索无果,建议确认“DDH2”是否为正确缩写(如可能指代“二氢二醇脱氢酶2”或特定基因编号),或补充研究领域(如癌症、酶学等)。
- 可使用关键词组合检索(如“DDH2 recombinant + [疾病/功能]”),或查阅相关综述追踪原始文献。
**Background of DDH2 Recombinant Protein**
DDH2 (Dihydrodiol Dehydrogenase 2), also known as carbonyl reductase 1 (CBR1), is a NADPH-dependent enzyme belonging to the short-chain dehydrogenase/reductase (SDR) superfamily. It plays a critical role in the metabolism of endogenous and exogenous compounds, including steroids, prostaglandins, and xenobiotics. DDH2 catalyzes the reduction of carbonyl groups in various substrates, contributing to detoxification pathways, drug metabolism, and the regulation of bioactive molecules. Its involvement in the inactivation of chemotherapeutic agents (e.g., anthracyclines) and the modulation of reactive aldehydes underscores its biomedical relevance.
Recombinant DDH2 protein is engineered using genetic cloning techniques, where the *DDH2* gene is expressed in heterologous systems like *E. coli* or mammalian cells. This allows large-scale production of the purified, functional enzyme for research and therapeutic applications. The recombinant form retains the enzymatic activity of native DDH2. enabling studies on its structural properties, substrate specificity, and interaction with inhibitors or activators.
Research on DDH2 recombinant protein has expanded due to its potential implications in cancer therapy, neurodegenerative diseases, and metabolic disorders. For instance, its role in mitigating oxidative stress by reducing cytotoxic aldehydes links it to neuroprotection, while its impact on drug resistance highlights its dual role in oncology. Additionally, DDH2 polymorphisms have been associated with variable drug responses, driving interest in personalized medicine.
Overall, DDH2 recombinant protein serves as a vital tool for elucidating biochemical pathways, developing targeted therapies, and exploring enzyme-driven mechanisms in health and disease. Its versatility continues to make it a focal point in both academic and pharmaceutical research.
×